Cediranib
Lung Metastases
City of Hope Medical CenterSmall moleculePhase 2Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Lung Metastases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB City of Hope Medical Center | Phase 3 | BB |
Abi-007 Celgene | Phase 2 | B |
Ipilimumab 7 Hills Pharma, LLC | Phase 2 | B |
azd0530 National Cancer Institute (NCI) | Phase 2 | B |
Imatinib National Cancer Institute (NCI) | Phase 2 | B |
View all 9 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →